rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-111-115rsp-2682Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSТрудности выбора генноинженерного биологического препарата для лечения псориаза и псориатического артритаDifficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritisМарусенкоИ. М.MarusenkoI. M.

185910, Петрозаводск, пр-т. Ленина, 33

feva@karelia.ruВезиковаН. Н.VezikovaN. N.

185910, Петрозаводск, пр-т. Ленина, 33

33, Lenin Avenue, Petrozavodsk 185910

КондричинаС. Н.KondrichinS. N.

33, Lenin Avenue, Petrozavodsk 185910

СильвестроваН. Д.SilvestrovN. D.ФГБОУ ВО «Петрозаводский государственный университет», медицинский институт, кафедра госпитальной терапииРоссияPetrozavodsk State University, Medical Institute, Department of Hospital TherapyRussian FederationГБУЗ «Республиканская больница им. В.А. Баранова»РоссияV.A. Baranov Republican HospitalRussian Federation201920032019571111115Copyright © Марусенко И.М., Везикова Н.Н., Кондричина С.Н., Сильвестрова Н.Д., 20192019Марусенко И.М., Везикова Н.Н., Кондричина С.Н., Сильвестрова Н.Д.Marusenko I.M., Vezikova N.N., Kondrichin S.N., Silvestrov N.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2682

В статье представлено собственное клиническое наблюдение пациентки, страдающей тяжелой формой псориаза и псориатическим артритом. Недостаточная эффективность системной терапии псориаза потребовала подключения генно-инженерных биологических препаратов, но проведение этой терапии было сопряжено с трудностями. Особенностями данного наблюдения являются развитие эритродермической формы псориаза на фоне лечения инфликсимабом и успешное применение в лечении псориаза препарата абатацепт, который не зарегистрирован в России в качестве средства для терапии данного заболевания.

The article presents a clinical observation of a patient with severe psoriasis and psoriatic arthritis. Due to insufficient efficacy of systemic therapy of psoriasis biologic disease-modifying therapy was started, but it was associated with difficulties. Development of erythrodermic form of psoriasis was observed during treatment with infliximab and abatacept was successfully used though it is not registered inRussiafor the treatment of psoriasis.

псориазпсориатический артритметотрексатинфликсимабабатацептустекинумабpsoriasispsoriatic arthritismethotrexateinfliximababataceptustekinumabReferencesNestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(12):496-509. doi: 10.1056/NEJMra0804595Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(12):496-509. doi: 10.1056/NEJMra0804595Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983-94. doi: 10.1016/S0140-6736(14)61909-7Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983-94. doi: 10.1016/S0140-6736(14)61909-7Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:569-79. doi: 10.1016/j.rdc.2015.07.003Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:569-79. doi: 10.1016/j.rdc.2015.07.003Российское общество дерматовенерологов и косметологов. Общероссийская общественная организация «Ассоциация ревматологов России». Федеральные клинические рекомендации по ведению больных псориатическим артритом. Москва; 2015. С. 41 [Russian society of dermatovenerologists and cosmetologists. All-Russian public organization «Association of Rheumatologists of Russia». Federal clinical guidelines for the management of patients with psoriatic arthritis. Moscow; 2015. P. 41 (In Russ.)].Российское общество дерматовенерологов и косметологов. Общероссийская общественная организация «Ассоциация ревматологов России». Федеральные клинические рекомендации по ведению больных псориатическим артритом. Москва; 2015. С. 41 [Russian society of dermatovenerologists and cosmetologists. All-Russian public organization «Association of Rheumatologists of Russia». Federal clinical guidelines for the management of patients with psoriatic arthritis. Moscow; 2015. P. 41 (In Russ.)].Mease P, Armstrong A. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423-41. doi: 10.1007/s40265-014-0191-yMease P, Armstrong A. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423-41. doi: 10.1007/s40265-014-0191-yCoates L, Kavanaugh A, Mease P, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016;68(5):1060-71. doi: 10.1002/art.39573Coates L, Kavanaugh A, Mease P, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016;68(5):1060-71. doi: 10.1002/art.39573Коротаева ТВ. Прогресс в лечении псориатического артрита. Фарматека. 2015;(7):21-7 [Korotaeva TV. Progress in the treatment of psoriatic arthritis. Farmateka. 2015;(7):21-7 (In Russ.)].Коротаева ТВ. Прогресс в лечении псориатического артрита. Фарматека. 2015;(7):21-7 [Korotaeva TV. Progress in the treatment of psoriatic arthritis. Farmateka. 2015;(7):21-7 (In Russ.)].Коротаева ТВ, Насонов ЕЛ. Стандарты терапии псориатического артрита. Научно-практическая ревматология 2009;47(3):29-37 [Korotaeva TV, Nasonov EL. Standards of therapy of psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):29-37 (In Russ.)]. doi: 10.14412/1995-4484-2009-1310Коротаева ТВ, Насонов ЕЛ. Стандарты терапии псориатического артрита. Научно-практическая ревматология 2009;47(3):29-37 [Korotaeva TV, Nasonov EL. Standards of therapy of psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):29-37 (In Russ.)]. doi: 10.14412/1995-4484-2009-1310Palfreeman A, McNamee K, McCann F. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201-10. doi: 10.2147/DDDT.S32713Palfreeman A, McNamee K, McCann F. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201-10. doi: 10.2147/DDDT.S32713Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668-77. doi: 10.1111/j.1365-2133.2012.11168.xPapp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668-77. doi: 10.1111/j.1365-2133.2012.11168.xНасонов ЕЛ. Перспективы применения блокатора костимуляции Т-лимфоцитов абатацепта при ревматоидном артрите. Клиническая фармакология и терапия. 2009;(1):45-52 [Nasonov EL. Prospects for the use of an abatacept T-lymphocyte costimulation blocker in rheumatoid arthritis. Klinicheskaya Farmakologiya i Terapiya. 2009;(1):45-52 (In Russ.)].Насонов ЕЛ. Перспективы применения блокатора костимуляции Т-лимфоцитов абатацепта при ревматоидном артрите. Клиническая фармакология и терапия. 2009;(1):45-52 [Nasonov EL. Prospects for the use of an abatacept T-lymphocyte costimulation blocker in rheumatoid arthritis. Klinicheskaya Farmakologiya i Terapiya. 2009;(1):45-52 (In Russ.)].Moreland LW, Alten R, van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470-9. doi: 10.1002/art.10294Moreland LW, Alten R, van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470-9. doi: 10.1002/art.10294Муравьев ЮВ. Какие неблагоприятные реакции на генноинженерные биологические препараты относят к парадоксальным? Научно-практическая ревматология. 2018;56(4):531-4 [Muravyev YuV. What adverse reactions to biological agents are paradoxical? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(4):531-534 (In Russ.)]. doi: 10.14412/1995-4484-2018-531-534Муравьев ЮВ. Какие неблагоприятные реакции на генноинженерные биологические препараты относят к парадоксальным? Научно-практическая ревматология. 2018;56(4):531-4 [Muravyev YuV. What adverse reactions to biological agents are paradoxical? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(4):531-534 (In Russ.)]. doi: 10.14412/1995-4484-2018-531-534Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5:421-31. doi: 10.1586/eci.09.18Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5:421-31. doi: 10.1586/eci.09.18Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001. doi: 10.1002/art.23835Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001. doi: 10.1002/art.23835Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40. doi: 10.1016/j.semarthrit.2010.04.003Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40. doi: 10.1016/j.semarthrit.2010.04.003Belinchon I, et al. Successful treatment of life-threatening erythrodermic psoriasis with infliximab. J Am Acad Dermatol. 2009;60(3):171.Belinchon I, et al. Successful treatment of life-threatening erythrodermic psoriasis with infliximab. J Am Acad Dermatol. 2009;60(3):171.Takahashi MDF, Castro LGM, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157(4):828-31. doi: 10.1111/j.1365-2133.2007.08111.xTakahashi MDF, Castro LGM, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157(4):828-31. doi: 10.1111/j.1365-2133.2007.08111.xLivia AT, Antonio JR, Mathias CE, Pozetti EMO. Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis. J Anais Brasil Dermatol. 2017;92(5):743-5. doi: 10.1590/abd1806-4841.20176565Livia AT, Antonio JR, Mathias CE, Pozetti EMO. Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis. J Anais Brasil Dermatol. 2017;92(5):743-5. doi: 10.1590/abd1806-4841.20176565Westhovens R, Kremer J, Moreland L, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5 year extended phase IIB study. J Rheumatol. 2009;36:736-42. doi: 10.3899/jrheum.080813Westhovens R, Kremer J, Moreland L, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5 year extended phase IIB study. J Rheumatol. 2009;36:736-42. doi: 10.3899/jrheum.080813Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86-94. doi: 10.1136/annrheumdis-2013-203843Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86-94. doi: 10.1136/annrheumdis-2013-203843Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Клиническая фармакология и терапия. 2016;25(1):67-76 [Nasonov EL. Pharmacotherapy of rheumatoid arthritis: Russian and international recommendations. Klinicheskaya Farmakologiya i Terapiya. 2016;25(1):67-76 (In Russ.)].Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Клиническая фармакология и терапия. 2016;25(1):67-76 [Nasonov EL. Pharmacotherapy of rheumatoid arthritis: Russian and international recommendations. Klinicheskaya Farmakologiya i Terapiya. 2016;25(1):67-76 (In Russ.)].Tanita K, Fujimura T, Kakizaki A, et al. Psoriasiform drug eruption caused by abatacept: immunohistochemical investigation of STAT signaling. Case Rep Dermatol. 2015;7:166-70. doi: 10.1159/000437415Tanita K, Fujimura T, Kakizaki A, et al. Psoriasiform drug eruption caused by abatacept: immunohistochemical investigation of STAT signaling. Case Rep Dermatol. 2015;7:166-70. doi: 10.1159/000437415Smith J, Cline A, Feldman SR. Advances in Psoriasis. South Med J. 2017;110(1):65-75. doi: 10.14423/SMJ.0000000000000596Smith J, Cline A, Feldman SR. Advances in Psoriasis. South Med J. 2017;110(1):65-75. doi: 10.14423/SMJ.0000000000000596Коротаева ТВ, Корсакова ЮЛ. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60-9 [Korotaeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):60-69 (In Russ.)]. doi: 10.14412/1995-4484-2018-60-69Коротаева ТВ, Корсакова ЮЛ. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60-9 [Korotaeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):60-69 (In Russ.)]. doi: 10.14412/1995-4484-2018-60-69Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176Huynh D, Kavanaugh A. Psoriatic Arthritis: Current Therapy and Future Approaches. Rheumatology. 2015;54(1):20-8. doi: 10.1093/rheumatology/keu237Huynh D, Kavanaugh A. Psoriatic Arthritis: Current Therapy and Future Approaches. Rheumatology. 2015;54(1):20-8. doi: 10.1093/rheumatology/keu237Корсакова ЮЛ, Станислав МЛ, Денисов ЛН, Насонов ЕЛ. Устекинумаб – новый препарат для лечения псориаза и псориатического артрита. Научно-практическая ревматология. 2013;51(2):170-80 [Korsakova YuL, Stanislav ML, Denisov LN, Nasonov EL. Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):170-80 (In Russ.)]. doi: 10.14412/1995-4484-2013-646Корсакова ЮЛ, Станислав МЛ, Денисов ЛН, Насонов ЕЛ. Устекинумаб – новый препарат для лечения псориаза и псориатического артрита. Научно-практическая ревматология. 2013;51(2):170-80 [Korsakova YuL, Stanislav ML, Denisov LN, Nasonov EL. Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):170-80 (In Russ.)]. doi: 10.14412/1995-4484-2013-646Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-74. doi: 10.1016/S0140-6736(08)60725-4Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-74. doi: 10.1016/S0140-6736(08)60725-4Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84. doi: 10.1016/S0140-6736(08)60726-6Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84. doi: 10.1016/S0140-6736(08)60726-6Griffiths CEM, Strober BE, van de Kerkhof P, et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med. 2010;362:118-28. doi: 10.1056/NEJMoa0810652Griffiths CEM, Strober BE, van de Kerkhof P, et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med. 2010;362:118-28. doi: 10.1056/NEJMoa0810652Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018 Feb;19(1):1-13. doi: 10.1007/s40257-017-0328-3Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018 Feb;19(1):1-13. doi: 10.1007/s40257-017-0328-3Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706-14.Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706-14.Egeberg A. Safety, efficacy and drug survival of biologics and biosimilars for moderate-tosevere plaque psoriasis. Br J Dermatol. 2018;178(2):509-19. doi: 10.1111/bjd.16102Egeberg A. Safety, efficacy and drug survival of biologics and biosimilars for moderate-tosevere plaque psoriasis. Br J Dermatol. 2018;178(2):509-19. doi: 10.1111/bjd.16102Коротаева ТВ, Логинова ЕЮ. Иммунопатогенетические механизмы действия устекинумаба – нового лекарственного средства для лечения псориатического артрита и псориаза. Современная ревматология. 2015;9(2):51-6 [Korotaeva TV, Loginova EYu. Immunopathogenetic mechanisms of action of ustekinumab, a new drug for treatment of psoriatic arthritis and psoriasis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):51-6 (In Russ.)]. doi: 10.14412/1996-7012-2015-2-51-56Коротаева ТВ, Логинова ЕЮ. Иммунопатогенетические механизмы действия устекинумаба – нового лекарственного средства для лечения псориатического артрита и псориаза. Современная ревматология. 2015;9(2):51-6 [Korotaeva TV, Loginova EYu. Immunopathogenetic mechanisms of action of ustekinumab, a new drug for treatment of psoriatic arthritis and psoriasis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):51-6 (In Russ.)]. doi: 10.14412/1996-7012-2015-2-51-56Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an antiIL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an antiIL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741Kavanaugh A, Puig L, et al, on behalf of the PSUMMIT 1 Study Group. Manitenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67:1739-49. doi: 10.1002/acr.22645Kavanaugh A, Puig L, et al, on behalf of the PSUMMIT 1 Study Group. Manitenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67:1739-49. doi: 10.1002/acr.22645McInnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis. 2012;71(Suppl):107-48.McInnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis. 2012;71(Suppl):107-48.McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3 multicentre, double blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-9. doi: 10.1016/S0140-6736(13)60594-2McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3 multicentre, double blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-9. doi: 10.1016/S0140-6736(13)60594-2

The authors declare that there are no conflicts of interest present.